Metformin And Aging: A Review Part 1
May 24, 2022
Please contact oscar.xiao@wecistanche.com for more information
Keywords: Rejuvenation·Longevity·Health span·Metformin·Fisetin
Abstract Metformin is sometimes proposed to be an"anti-aging" drug, based on preclinical experiments with lower-order organisms and numerous retrospective data on beneficial health outcomes for type2 diabetics. Large prospective,placebo-controlled trials are planned, in the pilot stage or running, to find a new use(or indication) for an aging population. As one of the metformin trials has"frailty" as its endpoint, similar to a trial with a plant-derived senolytic, the latter class of novel anti-aging drugs is briefly discussed. Concerns exist not only for vitamin B12 and B。deficiencies but also about whether there are adverse effects of metformin on individuals who try to remain healthy by maintaining cardiovascular fitness via exercise.
Introduction
Confronted with the task to write a review on"metformin and aging," it was decided to extract information from the most recent literature relevant to humans, focusing on planned or ongoing clinical trials. Mechanisms of action are briefly discussed. A detailed analysis of the evidence for metformin to extend the life of model organisms follows. sistanche Anti-aging research is a hot yet not unproblematic topic, as will be exemplified. A 2017 review[1] lists 16 biotech companies which develop drugs to fight aging and/or age-related diseases, 5" big data"anti-aging enterprises,and7stem cell/regeneration companies. Among the 5 big data companies is Calico Life Sciences LLC," one of Google's moonshot projects."The unique features of the ground-dwelling-ked mole rat, which lives about 10 times longer than a mouse, develops almost no cancer, and defies the Gompertz law(see online suppl. Fig. S1; for all online suppl. material, see www.karger.com/doi/10.1159/000502257), seems to be of interest to Calico. Rochelle Buffenstein is now a senior staff member of the company [2](Box 1 [3-5).

Please click here to know more
Longevity and Lifespan
Life extension-as a simple read-out of slowing aging by manipulation of model organisms with either drugs or, e.g, dietary restrictions-is enjoying a prominent place in imaging research. This approach was stimulated by observations with the mTORCl (mechanistic target of rapamycin complex1)inhibitor rapamycin in 2009 [6] when the drug was given more or less accidentally [7] to 600-day-old mice. Life was extended by 28 and 38% for
Dedicated to em.O.Univ.Prof. Dr.med. what is cistanche Georg Wickon occasion of his 80th birthday.

Fig.1.The three promises of anti-aging research. The painting"La Fontaine de Jouvence" by Paul-Jean-Louis Gervais shows an example of an artist's impression of the"Fountain of Youth" with the three promises: "healthspan," rejuvenation," and"longevity."Drugs(fisetin, rapamycin, and metformin) that are tested in clinical trials or under development for age-related diseases, and are propagated to fulfill one or even all of the promises, are shown for illustrative purposes. Mechanisms relevant to anti-aging are displayed by solid arrows with a plus or a minus sign. Interrupted arrows indicate activities reported in the preclinical literature without the identification of a primary molecular drug-receptor. The "classic" molecular target for metformin is complex I of the mitochondrial respiratory chain (see main text). An increased cellular ADP/ATP ratio upon metformin enrichment in the mitochondrial matrix leads to activation of AMPK. Active AMPK inhibits mTORC1 directly by phosphorylation of RAPTOR and indirectly by activating TSC2, one subunit of TSC. Whereas several other metformin targets in addition to complex I am discussed in the literature, rapamycin, by forming a complex with FKBP12, is exquisitely selective of mTORCl; there are no"off-target" binding sites. In contrast, fisetin, similar to other plant polyphenols, has multiple cellular actions (antioxidant, kinase inhibition, etc.; see main text and Schubert et al. [21]). Preclinical assays with laboratory mice, sometimes genetically modified, use an extension of lifespan and prolonged time periods of being free from age-related symptoms as important read-outs. See online suppl. Fig. S1 for the theoretically ultimate result of any anti-aging research; it exemplifies an"exceptional model for biogerontology"[101], the naked mole-rat. Anti aging cistanche These small rodents are not treated with drugs. Possible exceptions are compounds, produced by their intestinal microbiome, as the animals practice coprophagy. Naked mole rats stay "forever young and healthy" and survive their rat and mice counterparts treated with senolytics or any other drug by at least an order of magnitude. Painting: Capitole Toulouse, Salle des Illus-tres, Paul Gervais, 1908 (public domain). males and females, respectively. Analogs of rapamycin are in early clinical studies for age-related diseases [8], and the parent, off-patent drug was recently proposed for the prevention of Alzheimer's disease [9].
Rejuvenation by Elimination of Senescent Cells The term"rejuvenation" was used for analytics by Chang et al.[10].One of the hallmarks of aging is an increased number of "senescent" cells[1]. These irreversibly growth-arrested cells are resistant to apoptosis, and many age-related diseases are claimed to be linked to cellular senescence[12,13]. cistanche benefícios Senescent cells secrete a variety of bioactive factors(senescence-associated secretory phe-notype[SASP]). The SASP may be harmful to neighbor cells and even induce senescence [14].

Cistanche can anti-aging
Compounds that selectively eliminate senescent cells in cell culture or in rodents are classified as senolytics; compounds that suppress the SASP aretermedsenomor-phics[15]. The first molecules, claimed to be discovered by "bioinformatics"[16] but more likely by"phenotypic screening"[17], were dasatinib(a Federal Drug Admin-istration[FDA]-approved kinase inhibitor) and quercetin. When the (so-called) Koch-like criteria in preclinical testing were fulfilled [18], dasatinib and quercetin, as a fixed-dose combination, entered the first clinical trial in an open-label pilot study (NCT02874989)for patients with idiopathic pulmonary fibrosis [19].
Fisetin is another senolytic, tested in a clinical trial for age-related disorders(NCT03675724; AFFIRM-LITE). Fisetin also met the Koch-like criteria [20] and was pat-"Viviremos 135 anos!"("We will live for 135 years") was on the title page of the Spanish newspaper"El Mundo" on October 15, 2015. Lauded were Spanish scientists who published a paper in Nature Cell Biology [3]. Therein, the role of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB) and its downstream targets, such as disruptor of telomeric silencing 1-like(DOT1L), which is a histone H3(H3K79)methyltransferase, were propagated as targets for"rejuvenation."Three years earlier, the authors had reported that sodium salicylate (200 mg/kg by daily i.p. injection)greatly prolonged life in progeria mouse models [4]. It took 4 years until the 2015 paper[3] was retracted by Nature Cell Biology in March 2019 [5].In January 2019, another 8 publications from the same group were retracted from the Journal of Biological Chemistry. This illustrates that in the rather young scientific discipline of anti-aging research, competition is fierce and reproducibility by other, independent research groups is most important. The retractions finally occurred because of numerous comments and complaints, especially about "photoshopping"(see https://pubpeer.com/).

ented for improving memory(US7897637B2). Fisetin is one of several other compounds postulated to act as "geroneuro protectors"[21]. Fisetin and its major metabolite Geraldo apparently cross the blood-brain barrier when given orally to mice[22]. Typical for plant xenobiotics and similar to quercetin, fisetin undergoes multiple biotransformations. More than 50 metabolites were identified in rodents[23]. Fisetin is marketed as a nutraceutical (e.g., under the trade name Novusetin).
The interested public apparently screens ClinicalTri-als.gov for ongoing anti-aging studies and immediately started consuming fisetin, often together with quercetin and reduced nicotinamide adenine dinucleotide(NADH)boosters, either daily or twice a week(as in the clinical trial), and report their self-experimental results on a website [24].
HealthSpan
Matt Kaeberlein recently proposed to refrain from using the term healthspan in the scientific literature as health is not a binary trait with only two states(good or bad)[25]. However, it is used in numerous preclinical publications to emphasize that an intervention (with a drug or otherwise) prolongs not only the lifespan but also the percentage of time without any health deficits, as defined by the authors.
In contrast to rapamycin, where data from all preclinical trials on mouse models and other lower-order organisms prove that the drug increases the lifespan("longevity"), there is little such evidence for metformin (see below). Rapamycin also increases the health span or even reverses age-related diseases("rejuvenation")in worms, flies, mice, rats, and dogs [9].
Metformin's Mechanism of Action
Metformin Stimulates Hormone Secretion from the Gut Metformin is only active in type2 diabetes (T2D)/pre-diabetes when applied orally. The usual dose of an immediate-release formulation is around2 per day(12 mmol). About 6 mmol are excreted daily via the kidneys(active secretion). Kidney cells as well as epithelia in the urinary tract are exposed to concentrations higher than 4 mM. The other half of the drug is lost in the feces [26]. The colon is exposed to concentrations of up to 40 mm. Concentrations of metformin in human post-dose jejunal biopsies are 4,000 μmol per kg 【27】, and in colon biopsies (steady-state) they are between 26 and 1,820 μmolper kg [28].
It is not known in which cellular compartment (cytosol, mitochondrion, endoplasmic reticulum, or endo-/ly-lysosomes) the drug is sequestered. Previously, it has been postulated that the liver is the primary target organ of the drug. This view has changed, as the intestine(uptake into enterocytes and enteroendocrine cells is mediated by specific carriers)is now recognized to be responsible for most of the antidiabetic(and preventive) activity [29]. The evidence is based on the efficacy of a delayed-release formulation that spares the upper part of the gut(duodenum and jejunum) with lower systemic availability as well as liver exposure [30], and on clinical studies with antagonists which block the gut hormone glucagon-like peptide-1(GLP-1) [31]. In addition to GLP-1, plasma levels of two other hormones, peptide YY(PYY) and growth/differentiation factor 15(GDF15), are increased significantly under metformin therapy. The latter, produced mainly in the intestine via the "integrated stress response"[32], acts exclusively on neurons of the hindbrain (area posture ma) to control appetite, food intake, body weight, and plasma levels correlate with benefits in prediabetes [33].
Metformin Increases the Activity of Adenosine Monophosphate-Activated Protein Kinase
Adenosine monophosphate-activated protein kinase (AMPK) activity is increased upon chronic metformin dosing in human skeletal muscle[34] and adipose tissue [35]. Activation of AMPK is also suggested to participate in the acute release of the gut hormones GLP-1 and PYY from human mucosal preparations, as metformin stimulation is blocked by an inhibitor of the kinase[36].AMPK can be activated by the"canonical" pathway (increase in adenosine diphosphate/adenosine triphosphate [ADP/ATP] ratio and phosphorylation by upstream liver kinase B1 [LKB1])or by AMP-independent mechanisms [37]including a lysosomal pathway triggered by a decrease in fructose 1,6-bisphosphate [38].
Mitochondrial Complex IInhibition, Uncoupling, or Blocking of Lysosomal Vacuolar ATPase?

The classic"receptor"for"antidiabetic"biguanides (metformin <buformin<phenformin) is mitochondrial complex [39]. One other postulated mitochondrial tar-get (mitochondrial glycerol phosphate dehydrogenase)was proven to be an experimental artifact [40]. Purified complex I can be inhibited by the antidiabetic as well as the antimalarial biguanides cycloguanil and proguanil. The two latter biguanides do not inhibit complex I in in-tact mitochondria, nor do they increase AMPK in intact cells. This has led to the proposals that(a) a specific carrier exists in the inner mitochondrial membrane and (b)the negative membrane potential (-180 mV)enriches the antidiabetic drugs from micromolar cytosolic to high millimolar concentrations in the matrix. As a consequence, so the "inhibitory" hypothesis, the ADP/ATP ratio increases. Cistanche Extract Anti Radiation Metformin is also suggested to act as a"mild uncoupler"[41]. Metformin and phenformin are indeed potent inhibitors(1 uM)in isolated mitochondria, blocking retrograde electron transport and peroxide production, similar to an uncoupler [42].
As an alternative to the mitochondrial pathway (com-plex I "inhibition" and/or"uncoupling"), direct activation of AMPKand inhibition of mTORCl via blockage of lysosomal vacuolar ATPase(V-ATPase) was postulated [43]. As of April 2019, neither a structure-activity relationship for guanidines, as for mitochondria and complex I, nor dose responses have been reported. Likewise, the subunit of the V-ATPase postulated to bind the drug has not been published.
This article is extracted from Gerontology 2019;65:581–590 582 DOI: 10.1159/000502257






